OvaScience Inc. (NASDAQ:OVAS)’s share price dropped 2.5% during trading on Friday . The stock traded as low as $6.28 and last traded at $6.29, with a volume of 246,873 shares changing hands. The stock had previously closed at $6.45.

OVAS has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, August 5th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Leerink Swann reissued a “hold” rating and issued a $7.00 target price (up from $6.00) on shares of OvaScience in a report on Sunday, May 8th. Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. Finally, Zacks Investment Research raised shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Wednesday, August 10th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $10.98.

The stock has a 50 day moving average price of $5.75 and a 200 day moving average price of $7.09. The stock’s market cap is $224.75 million.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.16. The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. During the same quarter in the previous year, the business earned ($0.64) earnings per share. OvaScience’s revenue was up 530.0% compared to the same quarter last year. On average, analysts predict that OvaScience Inc. will post ($2.66) EPS for the current year.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.